About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
IP: -
1) To identify by proteomic analysis of cerebrospinal fluid new regulators of food intake. 2) To determine the influence of SHBG/sex-steroids on fat properties and distribution and the incidence of diabetes. 3) To investigate the role of the mitochondria in obesity, insulin resistance and type 2 diabetes.
A new approach using integrated biological systems.This is the main area of our research.
IP: Rafael Simó Canonge Collaborators: Miriam Izquierdo Sans Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 111758 Reference: PREP2022-000737 Duration: 01/03/2024 - 29/02/2028
IP: Andreea Ciudin Mihai Collaborators: Cristina Gamez Cenzano, Eduard Rodenas Alesina, Ana Marti Delgado, Fiorella Ximena Palmas Candia, Bruno García del Blanco, Ana Belén Méndez Fernández, Ana Maria Ciscar Bellés, Aleix Olivella San emeterio, Marta Comas Martinez, Alvaro Calabuig Goena, Enzamaría Fidilio Meli, Marco Tomasino Funding agency: Instituto de Salud Carlos III Funding: 165000 Reference: PI23/01209 Duration: 01/01/2024 - 31/12/2026
IP: David Martinez Selva Collaborators: Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina, Pilar Costa Forner Funding agency: Instituto de Salud Carlos III Funding: 190000 Reference: PI23/00544 Duration: 01/01/2024 - 31/12/2026
IP: David Martinez Selva Collaborators: Lidia Fuertes Rioja Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 370568 Reference: CPP2022-009831 Duration: 01/07/2023 - 30/06/2026
The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.
The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
